TSH Derangement in Thyroid Cancers and Nodules

TSH Derangement in Thyroid Cancers

TSH is a trophic hormone that can stimulate the growth of cells derived from thyroid follicular epithelium, which is why TSH suppression is part of treatment for patients with papillary, follicular, or Hürthle cell carcinoma, according to the National Comprehensive Cancer Network 1
For patients with known residual thyroid carcinoma or at high risk for recurrence, TSH levels should be maintained below 0.1 mU/L as part of treatment, as recommended by the National Comprehensive Cancer Network 1

Papillary thyroid carcinoma, which accounts for approximately 80% of thyroid cancers, typically presents as a cold nodule, according to the National Comprehensive Cancer Network 1
Follicular thyroid carcinoma (11% of thyroid cancers) also commonly presents as a cold nodule, as stated by the National Comprehensive Cancer Network 1
Hürthle cell carcinoma (3% of thyroid cancers) typically presents as a cold nodule, according to the National Comprehensive Cancer Network 1
Medullary thyroid carcinoma (4% of thyroid cancers) and anaplastic thyroid carcinoma (2% of thyroid cancers) also typically present as cold nodules, as reported by the National Comprehensive Cancer Network 1

TSH measurement should be performed as part of the initial workup for thyroid nodules, as recommended by the National Comprehensive Cancer Network 1 and 2
Ultrasound of the thyroid and central neck is recommended for evaluation of thyroid nodules, according to the National Comprehensive Cancer Network 1

TSH suppression therapy is an important part of treatment for differentiated thyroid cancer to prevent stimulation of residual cancer cells, as stated by the National Comprehensive Cancer Network 1
Routine monitoring of TSH levels is essential in the follow-up of patients with thyroid cancer, according to the National Comprehensive Cancer Network 4